Bone Microcirculation After Extracorporeal Shock Wave Therapy
NCT ID: NCT02424084
Last Updated: 2023-02-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2015-03-31
2023-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparing the Effects of Extracorporeal Shockwave Therapy and Splinting in the Treatment of Trigger Finger
NCT06746974
FlexWave Trial: Efficacy of Extracorporeal Shock Wave Therapy in Post-Stroke Upper Limb Spasticity
NCT06365476
Extracorporeal Shock Wave Therapy for Pain-Relief After Arthroscopy for Osteochondral Lesions of the Talus
NCT03750253
Clinical Trial to Evaluate the Adjuvant Effect of Shock Wave Therapy in the Insertional Achilles Tendinopathy
NCT02757664
Acute Effects of Interferential Current on Edema, Pain and Muscle Strength in Patients With Distal Radius Fracture
NCT03438864
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intact scaphoid bone
Group A (n=20): Consent-capable male and female patients ≥18 years of age who have an intact scaphoid.
Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Extracorporeal Shock Wave Therapy
Intact metacarpal bone
Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metacarpal bone.
Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Extracorporeal Shock Wave Therapy
Fractured scaphoid bone
Group C (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured scaphoid.
Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Extracorporeal Shock Wave Therapy
Fractured metacarpal bone
Group D (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured metacarpal bone.
Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Extracorporeal Shock Wave Therapy
Intact metatarsal bone
Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metatarsal bone.
Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Extracorporeal Shock Wave Therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Extracorporeal Shock Wave Therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metacarpal bone.
* Group C (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured scaphoid.
* Group D (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured metacarpal bone.
Exclusion Criteria
* scar tissue above scaphoid or metacarpal bone
* osteoporosis or comparable bone disease
* medication that influences bones
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Schleswig-Holstein
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tobias Kisch
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tobias Kisch, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital Schleswig-Holstein
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Schleswig-Holstein
Lübeck, Schleswig-Holstein, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14-266-4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.